{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:14:02Z","timestamp":1760145242508,"version":"build-2065373602"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:00:00Z","timestamp":1698710400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista Portuguesa de Cardiologia"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.repc.2023.10.005","type":"journal-article","created":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T21:54:18Z","timestamp":1698789258000},"page":"221-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one"],"prefix":"10.1016","volume":"43","author":[{"given":"Jorge","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catarina D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Fresco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Fernandez-Llimos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.repc.2023.10.005_bib0050","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.repc.2022.02.014","article-title":"Potential use of renin\u2013angiotensin\u2013aldosterone system inhibitors to reduce COVID-19 severity","volume":"42","author":"Gon\u00e7alves","year":"2023","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2023.10.005_bib0055","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.2165\/00003495-199856060-00007","article-title":"Telmisartan","volume":"56","author":"McClellan","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.repc.2023.10.005_bib0060","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.repc.2023.06.003","article-title":"Reply to: RAAS inhibitors in COVID-19: not all are created equal!","volume":"42","author":"Gon\u00e7alves","year":"2023","journal-title":"Rev Port Cardiol"},{"key":"10.1016\/j.repc.2023.10.005_bib0065","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1476-5381.1993.tb13800.x","article-title":"Pharmacological characterization of the novel nonpeptide angiotensin II receptor antagonist, BIBR 277","volume":"110","author":"Wienen","year":"1993","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.repc.2023.10.005_bib0070","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","article-title":"Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity","volume":"43","author":"Benson","year":"2004","journal-title":"Hypertension"},{"key":"10.1016\/j.repc.2023.10.005_bib0075","doi-asserted-by":"crossref","first-page":"C82","DOI":"10.1152\/ajpcell.00287.2006","article-title":"Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system","volume":"292","author":"Mehta","year":"2007","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.repc.2023.10.005_bib0080","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jacc.2004.03.065","article-title":"Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease","volume":"44","author":"Schieffer","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.repc.2023.10.005_bib0085","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s11906-006-0050-7","article-title":"Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress","volume":"8","author":"Ferder","year":"2006","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.repc.2023.10.005_bib0090","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11906-022-01207-3","article-title":"Renin\u2013angiotensin\u2013aldosterone inhibitors and COVID-19 infection","volume":"24","author":"Tsampasian","year":"2022","journal-title":"Curr Hypertens Rep"}],"container-title":["Revista Portuguesa de Cardiologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255123004602?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0870255123004602?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:15:03Z","timestamp":1760109303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0870255123004602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0870255123004602"],"URL":"https:\/\/doi.org\/10.1016\/j.repc.2023.10.005","relation":{},"ISSN":["0870-2551"],"issn-type":[{"type":"print","value":"0870-2551"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reply to: RAAS inhibitors in COVID-19: Not all are created equal. Telmisartan is the one","name":"articletitle","label":"Article Title"},{"value":"Revista Portuguesa de Cardiologia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2023.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.repc.2023.08.005","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedade Portuguesa de Cardiologia. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}